Date: Tuesday, May 2, 2017
Session Name: Poster Session D: Kidney: Cardiovascular and Metabolic
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
- Influence of Lipid Levels on Cardiovascular Events After Early Conversion from Calcineurin Inhibitor to Everolimus: 24 M Analysis of the ELEVATE Study.
- Evolution of Lipid Profile and Major Adverse Cardiac Events in Kidney Transplant Recipients Converted from Calcineurin Inhibitor to Everolimus: 24-Month Subanalysis from Elevate Study.
PURPOSE: Pretransplant (preTx) diabetes is an independent risk factor for cardiovascular (CV) events, and posttransplant (post-Tx) hyperlipidemia further increases CV risk. To analyze the influence of preTx diabetes on CV outcomes, a 24-month (M) analysis of lipid profiles and CV outcomes in diabetic kidney transplant recipients (KTxRs) from the ELEVATE (NCT01114529) study, receiving everolimus (EVR) or standard calcineurin inhibitor (CNI) regimen, was performed.
METHODS: In this 24M, open-label, multicenter study, KTxRs were randomized at 10-14 weeks post-Tx to receive EVR (N=360; C0: 6-10ng/mL) or continue standard CNI regimen (N=357; C0: tacrolimus [TAC] 5-10ng/mL/cyclosporine A [CsA] 100-250ng/mL). Total-, high-density lipoprotein (HDL)-, and low-DL (LDL)- cholesterol (C) and triglyceride levels and incidence of CV events, including major adverse cardiac events (MACE), were assessed up to M24.
RESULTS: A total of 66 and 42 patients in EVR and CNI arms had preTx diabetes, respectively. Within CNI arm, 29 and 13 patients received TAC and CsA, respectively. High total-C (28.8%) and coronary heart disease (35.7%) were the most prevalent baseline CV risk factors in EVR and total CNI arms, respectively (Table). At M24, all lipid levels were significantly higher in EVR vs TAC arm (P<0.05), but not between EVR and CsA arms. While hypertriglyceridemia was absent, hypercholesterolemia events reported as adverse events were comparable between arms (P>0.999). Overall MACE incidence was numerically lower in EVR (7.6%) vs TAC (10.3%) and CsA (15.4%), and incidence of ischemic coronary artery disease was significantly lower in EVR vs CsA arm (0.0% vs 21.4%; P<0.01). Other CV events were comparable between arms.
CONCLUSION: Lower frequency of CV events despite higher lipid abnormalities in EVR vs CNI arms indicates that hyperlipidemia with EVR-based regimen may not increase CV risk in KTxRs even in presence of preTx diabetes. Nevertheless, follow-up beyond 24M is required to establish the long-term benefit of EVR in these patients.
CITATION INFORMATION: van der Giet M, de Fijter J, Oppenheimer F, Russ G, Lopez P, Bader G, Cruzado J, Holdaas H. Lipid Abnormalities and Cardiovascular Events After Early Conversion to Everolimus in Kidney Transplant Recipients with Pretransplant Diabetes: 24-Month Analysis from Elevate Study. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Giet Mvander, Fijter Jde, Oppenheimer F, Russ G, Lopez P, Bader G, Cruzado J, Holdaas H. Lipid Abnormalities and Cardiovascular Events After Early Conversion to Everolimus in Kidney Transplant Recipients with Pretransplant Diabetes: 24-Month Analysis from Elevate Study. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/lipid-abnormalities-and-cardiovascular-events-after-early-conversion-to-everolimus-in-kidney-transplant-recipients-with-pretransplant-diabetes-24-month-analysis-from-elevate-study/. Accessed January 15, 2021.
« Back to 2017 American Transplant Congress